Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target

Syndax Pharmaceuticals is viewed favorably because Revuforj is showing strong clinical and real-world traction, including a 97% CRc with clean safety in frontline AML combination data and durable post-HSCT outcomes with a 1 year CIR of 11% and 2 year OS of 93% in CR2+ patients. The company is also expanding beyond a single asset by adding SNDX-62122 and SNDX-4321, which extend the menin and EGFR theses into larger addressable markets while preserving a capital-efficient path and leveraging existing discovery capabilities. Together with Niktimvo’s potential in IPF and other fibrotic diseases, these programs create multiple shots on goal and support a longer runway for commercial growth and value creation.

Syndax Pharmaceuticals is viewed negatively because its valuation depends on a highly speculative path to FY32 GAAP EPS of $5.61 and an NPV model discounted at 13.0%, leaving limited margin for disappointment. As a clinical-stage biopharmaceutical company, it faces meaningful clinical failure risk for revumenib, axatilimab, and entinostat, while regulatory delays or setbacks could materially impair progress. The company also faces intense competition from better-resourced commercial and development-stage peers and may need additional equity financing to fund development, which could dilute shareholders.